A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Miami
St. Jude Children's Research Hospital
Tianjin Medical University Cancer Institute and Hospital
University of Chicago
Mayo Clinic
Icahn School of Medicine at Mount Sinai
Hellenic Society of Hematology
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Stanford University
Stanford University
University of South Florida
M.D. Anderson Cancer Center
Duke University